<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Traumatic hyphema: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Traumatic hyphema: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Traumatic hyphema: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher M Andreoli, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew F Gardiner, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard G Bachur, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Trobe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria E Moreira, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H714239807"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Traumatic hyphema, or blood in the anterior chamber, is a common complication of blunt or penetrating injury to the eye and can result in permanent vision loss. Once life-threatening injuries are addressed, the goals of initial assessment include recognition and characterization of the hyphema as well as identification of associated orbital and ocular injuries. Although discussed separately, the assessment and management are, in practice, done together  (<a class="graphic graphic_table graphicRef74146" href="/d/graphic/74146.html" rel="external">table 1</a>).</p><p>If an orbital compartment syndrome or open globe is suspected, then emergent consultation with an ophthalmologist is critical to help preserve vision. In addition, optimal outcome following a hyphema depends upon early ophthalmologic intervention focused on prevention of rebleeding and avoidance of intraocular hypertension. In most instances, patients recover with vision intact. Vision loss is more likely in patients with large hyphemas, sickle hemoglobinopathies, or bleeding dyscrasias.</p><p>This review covers the initial and definitive management of traumatic hyphemas. Clinical features and diagnosis of traumatic hyphemas are discussed separately. (See  <a class="medical medical_review" href="/d/html/6570.html" rel="external">"Traumatic hyphema: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H714239849"><span class="h1">APPROACH</span><span class="headingEndMark"> — </span>A rapid overview summarizes the important clinical features and initial management of traumatic hyphema  (<a class="graphic graphic_table graphicRef74146" href="/d/graphic/74146.html" rel="external">table 1</a>).</p><p>The clinician should first address life-threatening and immediate vision-threatening conditions before proceeding with specific treatment of a traumatic hyphema as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Life-threatening trauma</strong> – Hyphema can occur as a result of blunt injury to the eye in the setting of a fall, blow to the head, or multiple trauma; or as a component of a penetrating injury. The standard trauma evaluation should be followed to evaluate for life-threatening injuries in multitrauma patients before attention is focused on the eye. (See  <a class="medical medical_review" href="/d/html/13854.html" rel="external">"Initial management of trauma in adults"</a> and  <a class="medical medical_review" href="/d/html/6571.html" rel="external">"Trauma management: Approach to the unstable child"</a> and  <a class="medical medical_review" href="/d/html/4826.html" rel="external">"Management of acute moderate and severe traumatic brain injury"</a>.)</p><p></p><p class="bulletIndent1">In patients requiring intubation, the potential for open globe or increased intraocular pressure presents relative contraindications for the use of <a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a>. However, premedication with <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> can mitigate increased intraocular pressure if true rapid sequence induction is necessary [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care", section on 'Paralysis with induction'</a> and  <a class="medical medical_review" href="/d/html/113029.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Medications for sedation and paralysis", section on 'Paralytic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate threats to vision</strong> – The clinician should assess for an orbital compartment syndrome  (<a class="graphic graphic_picture graphicRef95380" href="/d/graphic/95380.html" rel="external">picture 1</a>) or an open globe  (<a class="graphic graphic_picture graphicRef67579" href="/d/graphic/67579.html" rel="external">picture 2</a>) and seek emergent ophthalmologic consultation if either is present. (See  <a class="medical medical_review" href="/d/html/6513.html" rel="external">"Open globe injuries: Emergency evaluation and initial management", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/104455.html" rel="external">"Overview of eye injuries in the emergency department", section on 'Orbital compartment syndrome'</a>.)</p><p></p><p class="bulletIndent1">Patients with signs of an orbital compartment syndrome (eg, proptosis, decreased visual acuity, diffuse subconjunctival hemorrhage, tight eyelids) require emergent lateral canthotomy and inferior cantholysis to decompress the orbit. (See  <a class="medical medical_review" href="/d/html/13903.html" rel="external">"Approach to diagnosis and initial treatment of eye injuries in the emergency department", section on 'Orbital compartment syndrome'</a> and  <a class="medical medical_review" href="/d/html/104455.html" rel="external">"Overview of eye injuries in the emergency department", section on 'Orbital compartment syndrome'</a>.)</p><p></p><p class="bulletIndent1">A rapid overview provides key clinical findings and management of patients with an open globe  (<a class="graphic graphic_table graphicRef50022" href="/d/graphic/50022.html" rel="external">table 2</a>).</p><p></p><p class="headingAnchor" id="H714240009"><span class="h1">INDICATIONS FOR OPHTHALMOLOGY CONSULTATION OR REFERRAL</span><span class="headingEndMark"> — </span>Whenever possible, all patients with a traumatic hyphema warrant prompt evaluation by an ophthalmologist to provide a comprehensive eye examination, including intraocular pressure measurement. In addition, patients with the following findings warrant emergent consultation with an ophthalmologist with expertise in managing eye injuries:</p><p class="bulletIndent1"><span class="glyph">●</span>Orbital compartment syndrome (see  <a class="medical medical_review" href="/d/html/104455.html" rel="external">"Overview of eye injuries in the emergency department", section on 'Orbital compartment syndrome'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Open globe (see  <a class="medical medical_review" href="/d/html/6513.html" rel="external">"Open globe injuries: Emergency evaluation and initial management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Traumatic hyphema with any of the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large (grade III or IV) hyphemas  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef71507" href="/d/graphic/71507.html" rel="external">picture 3</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyphemas in patients with a bleeding tendency or sickle hemoglobinopathy (either disease or trait) as determined by history or screening during initial evaluation (see  <a class="medical medical_review" href="/d/html/6570.html" rel="external">"Traumatic hyphema: Clinical features and diagnosis", section on 'Predisposing conditions'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyphemas associated with elevated intraocular pressure</p><p></p><p>If prompt consultation with an ophthalmologist is not feasible but serious associated eye injury and elevated intraocular pressure can be reliably excluded, discussion with an ophthalmologist prior to emergency department discharge is suggested. These patients warrant timely referral for complete ophthalmologic examination within 24 hours.</p><p class="headingAnchor" id="H714240898"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The following general measures are recommended in patients with hyphema and comprise appropriate initial care  (<a class="graphic graphic_table graphicRef74146" href="/d/graphic/74146.html" rel="external">table 1</a>) [<a href="#rid2">2-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye shield</strong> – An eye shield should be placed over the affected eye as soon as possible and subsequently removed only as required for examination and imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bed rest and dim lighting</strong> – Limitation of activity to bed rest with bathroom privileges should occur until initial evaluation is complete. The patient should be placed in a dim, quiet room and should not read so that visual accommodation does not further stress injured blood vessels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevate the head of the bed</strong> – Elevation of the head to 30 degrees promotes inferior settling of blood in the anterior chamber away from the visual axis while maintaining arterial blood flow to the eye relative to the fully erect position [<a href="#rid2">2,3</a>]. Thirty degree elevation of the head also improves diagnosis of secondary hemorrhage and aids in clearance of the hyphema.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control pain</strong> – Pain control improves patient comfort and facilitates eye examination [<a href="#rid3">3</a>]. Topical analgesia with <a class="drug drug_general" data-topicid="9824" href="/d/drug information/9824.html" rel="external">proparacaine</a> or <a class="drug drug_general" data-topicid="10278" href="/d/drug information/10278.html" rel="external">tetracaine</a> may be applied temporarily in patients without an open globe; long term use may cause corneal toxicity. Dilating eye drops, discussed below, may also provide some pain relief. Nonsteroidal antiinflammatory agents (NSAIDS) are discouraged because of their platelet inhibiting properties.</p><p></p><p class="bulletIndent1">For patients in whom topical analgesia is inadequate, the clinician may consider oral or intravenous opioids. <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">Hydrocodone</a> or <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> in combination with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> is preferred to <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> because they are less prone to cause nausea and vomiting. Intravenous therapy with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> may be needed in patients with large hyphemas (grade III to IV  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>)) or associated traumatic injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treat nausea and prevent vomiting</strong> – Patients with nausea or vomiting require treatment with antiemetics, such as <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>, to prevent sudden increase in intraocular pressure caused by emesis [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dilating eye drops</strong> – For patients without narrow angle glaucoma, Cycloplegia, topically with <a class="drug drug_general" data-topicid="9307" href="/d/drug information/9307.html" rel="external">cyclopentolate</a> one percent (eg, Cyclogyl, Cylate, or Ocu-Pentolate), one drop, or <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> 0.25 percent one drop, often provides pain relief and allows for optimal examination of the posterior segment [<a href="#rid2">2-4</a>]. Dilating eye drops are <strong>contraindicated</strong> in patients with suspected open globe injury or narrow angle glaucoma [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correct coagulopathy</strong> – Patients with bleeding tendency, such as hemophilia, von Willebrand disease, or thrombocytopenia should receive appropriate treatment to restore clotting capability [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/d/html/1314.html" rel="external">"Treatment of bleeding and perioperative management in hemophilia A and B"</a> and  <a class="medical medical_review" href="/d/html/1372.html" rel="external">"von Willebrand disease (VWD): Treatment of major bleeding and major surgery"</a> and  <a class="medical medical_review" href="/d/html/5917.html" rel="external">"Immune thrombocytopenia (ITP) in children: Initial management"</a>.)</p><p></p><p class="bulletIndent1">If the patient is taking an anticoagulant, a decision should be made regarding appropriate interventions, including discontinuation and/or reversal of the anticoagulant effect with input from the consulting specialist. This must balance the relative benefits of anticoagulation for the individual patient. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H714240904"><span class="h1">OPHTHALMOLOGIC MANAGEMENT</span><span class="headingEndMark"> — </span>Once emergency management and evaluation are complete, an ophthalmologist must direct ongoing care of patients with traumatic hyphema because of the need for daily comprehensive eye examination, the risks of therapy, and the potential need for surgical intervention if medical therapy fails  (<a class="graphic graphic_table graphicRef74146" href="/d/graphic/74146.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H21824892"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Treatment of traumatic hyphema focuses on prevention of secondary hemorrhage and intraocular hypertension. Secondary hemorrhages usually result in hyphemas that are larger than the initial bleed and may increase the risk of vision loss [<a href="#rid3">3,4</a>]. (See <a class="local">'Outcomes'</a> below.)</p><p class="headingAnchor" id="H21825348"><span class="h3">Monitoring of intraocular pressure</span><span class="headingEndMark"> — </span>Daily monitoring of intraocular pressure is a cornerstone in the management of traumatic hyphema. Uncontrolled intraocular hypertension despite maximal medical therapy may cause optic nerve damage and is an indication for surgical intervention. Uncontrolled intraocular hypertension is defined as &gt;50 mmHg for five days, &gt;35 mmHg for seven days or, in patients with sickle hemoglobinopathy &gt;25 mmHg for &gt;24 hour [<a href="#rid4">4</a>]. (See <a class="local">'Surgical clot evacuation'</a> below and  <a class="medical medical_review" href="/d/html/6570.html" rel="external">"Traumatic hyphema: Clinical features and diagnosis", section on 'Predisposing conditions'</a>.)</p><p class="headingAnchor" id="H714240922"><span class="h3">Limitation of activity</span><span class="headingEndMark"> — </span>Although evidence of benefit is limited, limitation of activity for at least one week is a common component of ongoing treatment [<a href="#rid7">7</a>]. Observational studies and randomized trials comparing rest, head elevation, and occasional quiet ambulation in the hospital or at home have resulted in similar vision outcomes relative to strict bed rest [<a href="#rid4">4,7,8</a>]. Although evidence is lacking, reading is also restricted by many ophthalmologists because of the theoretical concern that accommodation further stresses injured blood vessels. If the hyphema is present at seven days after injury, then limitation of activity should be extended until it resolves.</p><p class="headingAnchor" id="H714240928"><span class="h3">Eye shield</span><span class="headingEndMark"> — </span>To avoid further injury to the affected eye, an eye shield should be worn at all times until the hyphema resolves or for at least one week [<a href="#rid2">2-4</a>]. A clear rigid shield may be used in monocular patients with injury to their only eye or in young children with concern for amblyopia.</p><p>Some ophthalmologists suggest an eye patch over the shield in patients at risk for corneal blood staining (ie, patients with a large hyphema, increased intraocular pressure, or both). The purpose of the patch is to prevent ambient light from reacting with porphyrins present in the anterior chamber from the degrading hemoglobin which may cause further endothelial damage. Alternatively, an opaque shield may be used. If either an opaque shield or patch over the shield is used in a young child, the duration of application should be limited to avoid amblyopia or strabismus [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/6255.html" rel="external">"Amblyopia in children: Classification, screening, and evaluation", section on 'Definition'</a>.)</p><p>As opposed to an eye shield, an occlusive monocular or binocular eye patch using gauze and topical antibacterial ointment does not improve outcomes in terms of ultimate visual acuity and is <strong>not</strong> a routine practice [<a href="#rid4">4,7</a>].</p><p class="headingAnchor" id="H714240934"><span class="h3">Cycloplegia</span><span class="headingEndMark"> — </span>For the management of pain, we suggest that patients <strong>without</strong> narrow angle glaucoma be treated with cycloplegic eye drops as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Adults – <a class="drug drug_general" data-topicid="9307" href="/d/drug information/9307.html" rel="external">Cyclopentolate</a> 1% (eg, Cyclogyl, Cylate, Ocu-Pentolate), one drop, three times daily or <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> 0.25%, one drop, twice daily </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children (&gt;3 years old) – <a class="drug drug_general" data-topicid="9307" href="/d/drug information/9307.html" rel="external">Cyclopentolate</a> 1%, one drop, two or three times daily or, to reduce frequency of eye drops, <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a> 1%, one drop daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants and young children (≤3 years old) – Avoid cycloplegic eye drops for pain relief because of increased risk of side effects. In patients with traumatic hyphema, cycloplegia often provides pain relief and permits optimal examination of the posterior segment [<a href="#rid2">2-4</a>]. Long-term eye dilation also prevents the development of posterior synechiae that can result in permanent iris dysfunction. However, based upon observational studies, cycloplegia does <strong>not</strong> prevent rebleeding [<a href="#rid9">9-11</a>].</p><p></p><p>Oral analgesics, other than nonsteroidal antiinflammatory agents, may also be prescribed if cycloplegia is contraindicated or does not provide adequate pain control.</p><p class="headingAnchor" id="H714240940"><span class="h3">Glucocorticoid eye drops</span><span class="headingEndMark"> — </span>In order to lower the risk of rebleeding, we suggest that patients with traumatic hyphema receive topical glucocorticoid eye drops rather than systemic glucocorticoids because topical steroid eye drops avoid the potential adverse effects of systemic glucocorticoid therapy (hyperactivity, sleep disturbance, hyperglycemia, systemic hypertension, and vomiting). Although evidence is lacking, topical steroids may also prevent posterior synechiae and treat iridocyclitis.</p><p>Several retrospective and unblinded prospective studies report a lower risk of rebleeding in patients who receive topical glucocorticoids (0 to 5 versus 3 to 14 percent in untreated patients) [<a href="#rid3">3,4,9,11-13</a>]. However, two small trials have failed to show a significant difference [<a href="#rid7">7</a>].</p><p>Patients receiving topical glucocorticoid drops require frequent serial examinations by an ophthalmologist to ensure no infection or corneal perforation occurs. Possible regimens include one drop of <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> acetate 1 percent ophthalmic drops or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> <a class="drug drug_general" data-topicid="10269" href="/d/drug information/10269.html" rel="external">sodium phosphate</a> 0.1 percent ophthalmic drops four times daily. Ocular hypertension may occur after more than seven days of use.</p><p class="headingAnchor" id="H11460044"><span class="h3">Determining sickle cell status</span><span class="headingEndMark"> — </span>Individuals with sickle cell disease and those with sickle cell trait are at increased risk for complications of traumatic hyphema, including rebleeding. Thus, testing for sickle cell status is warranted for all at-risk individuals with traumatic hyphema who do not have definitive information regarding their sickle cell status. (See  <a class="medical medical_review" href="/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders", section on 'Older children and adults'</a>.)</p><p class="headingAnchor" id="H714240952"><span class="h2">Patients with rebleeding</span><span class="headingEndMark"> — </span>Patients who have rebled warrant hospitalization for enforcement of activity restrictions, continuation of specific medical therapy, and frequent monitoring of intraocular pressure. Patients who develop intraocular hypertension that can’t be medically controlled, large persistent hyphemas (≥grade III for &gt;10 days)  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>), or early corneal blood staining meet criteria for surgical clot evacuation [<a href="#rid14">14</a>]. (See <a class="local">'Surgical clot evacuation'</a> below.)</p><p>The use of antifibrinolytics for the treatment of hyphema has largely fallen out of favor. In the past, patients with traumatic hyphema who had rebleeding sometimes received systemic <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a> (ACA) or <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> therapy. Systemic antifibrinolytics do reduce the risk of rebleeding but have significant adverse effects (eg, increased risk of thrombotic events including pulmonary embolism and myocardial infarction, bradycardia, or postural hypotension with syncope) and prolong clot resorption. Furthermore, limited evidence shows no benefit in terms of final visual acuity [<a href="#rid7">7</a>].</p><p>Topical ACA provides the theoretical benefit of clot stabilization while avoiding adverse systemic effects but is not widely available. Although limited evidence suggests that topical ACA has similar benefits to systemic ACA [<a href="#rid7">7</a>], results from clinical studies that have compared topical ACA with cycloplegic drops have not shown clear evidence of reduced rebleeding [<a href="#rid15">15-17</a>].</p><p class="headingAnchor" id="H714240958"><span class="h2">Patients with intraocular hypertension</span><span class="headingEndMark"> — </span>Topical therapy with agents that suppress aqueous flow, such as beta adrenergic blockers and carbonic anhydrase inhibitors, are frequently needed to treat increased intraocular pressure in patients with traumatic hyphema [<a href="#rid3">3</a>]. All topical agents can be absorbed systemically and may have adverse effects, therefore they should be used cautiously  (<a class="graphic graphic_table graphicRef76771" href="/d/graphic/76771.html" rel="external">table 3</a>).</p><p>When topical therapy is inadequate, oral therapy with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> (250 mg four times daily or 500 mg extended release [ER or "sequel"] two times daily) or <a class="drug drug_general" data-topicid="9625" href="/d/drug information/9625.html" rel="external">methazolamide</a> (25 to 50 mg two to three times daily) may be administered. </p><p>In addition, intravenous administration of <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> 1.5 g/kg over 45 minutes twice daily may be attempted in patients with uncontrolled intraocular hypertension despite topical therapy [<a href="#rid12">12</a>].</p><p>Carbonic anhydrase inhibitor or <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> administration is typically <strong>avoided</strong> in patients with sickle cell disease because of the theoretical risk of sickling caused by metabolic acidosis or volume depletion. Humidified transcorneal oxygen, delivered at 1 to 3 L/min has been associated with a rapid reduction in elevated intraocular pressure in one series of three patients with sickle hemoglobinopathy and may be an alternative for such patients when topical therapy with beta adrenergic blockers does not control intraocular pressure [<a href="#rid18">18</a>].</p><p>Uncontrolled intraocular hypertension (ie, ≥50 mmHg for &gt;5 days or, in patients with sickle hemoglobinopathy, &gt;25 mmHg for &gt;24 hours) despite maximal medical therapy is a potential indication for surgical anterior chamber clot evacuation. (See <a class="local">'Surgical clot evacuation'</a> below.)</p><p class="headingAnchor" id="H714240970"><span class="h2">Surgical clot evacuation</span><span class="headingEndMark"> — </span>Approximately 5 percent of patients with traumatic hyphema require surgery. Patients with sickle hemoglobinopathy, including sickle cell trait, and bleeding tendency are more likely to meet thresholds for surgical intervention [<a href="#rid2">2-4,19</a>]. (See  <a class="medical medical_review" href="/d/html/6570.html" rel="external">"Traumatic hyphema: Clinical features and diagnosis", section on 'Predisposing conditions'</a>.)</p><p>Potential indications for surgical anterior chamber clot evacuation include [<a href="#rid2">2-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Large persistent hyphemas (≥grade III for &gt;10 days)  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Early corneal blood staining</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled intraocular pressure (ie, ≥50 mmHg for &gt;5 days or, in patients with sickle hemoglobinopathy, &gt;25 mmHg for &gt;24 hours) despite maximal medical therapy</p><p></p><p class="headingAnchor" id="H21824032"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Several observational studies suggest that most patients can safely receive treatment for hyphema in the outpatient setting [<a href="#rid3">3,4,12,20-22</a>].</p><p>Hospital admission is warranted for the following patients [<a href="#rid2">2-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Large hyphemas (blood occupying 50 percent or more of the anterior chamber)  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyphemas with severely elevated intraocular pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Hyphemas in patients with sickle hemoglobinopathy (disease or trait)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with bleeding tendency or coagulopathy</p><p></p><p>Additional considerations regarding hospitalization include the inability to adhere to the rigorous regimen of restriction of activity, the inability to do multiple and frequent medication administration, or the inability to make daily travel to the ophthalmologist for examination [<a href="#rid2">2,4</a>].</p><p>Otherwise, for patients with traumatic hyphemas who can adhere to the treatment regimen, we suggest outpatient management. Successful outpatient management of traumatic hyphemas depends upon clear patient education. Patients and caregivers must understand the critical importance of minimizing activity, adherence to all medications, and compliance with daily ophthalmology examinations. Adherence is improved if medications and a medication schedule are provided to the patient prior to discharge.</p><p>Patients should be counselled to return for symptoms of rebleeding or elevated intraocular pressure (suddenly decreased vision and pain) or of retinal detachment (flashes, new floaters, or a shade descending over the vision).</p><p class="headingAnchor" id="H714240976"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Visual outcomes in patients with traumatic hyphemas are determined by a variety of factors as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Size of the hyphema</strong> – Grade I hyphemas or microhyphemas  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>) usually resolve in four to five days [<a href="#rid3">3</a>]. A final vision of 20/50 (6/18) or worse is seen in 50 to 75 percent of patients with grade III or IV hyphema  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>) as opposed to 10 percent or less of patients with either microhyphema or grade I hyphema [<a href="#rid3">3,23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraocular hypertension</strong> – Intraocular hypertension can cause permanent optic atrophy. Uncontrolled elevation in intraocular pressure is an indication for surgical clot evacuation. (See <a class="local">'Surgical clot evacuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Corneal blood staining</strong> – Corneal blood staining can occur with intraocular hypertension, large hyphemas, and when hyphemas persist. Corneal blood staining may threaten vision, especially when staining occurs in the visual axis [<a href="#rid3">3,4,23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rebleeding</strong> – Secondary hemorrhages usually result in hyphemas that are larger than the initial injury and can markedly increase the risk of vision loss in patients with microhyphema or grade I hyphema [<a href="#rid3">3,4,23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated injury</strong> – Visual prognosis is also affected dramatically by the presence of other injuries to the vitreous, retina, and optic nerve. As many as 14 percent of hyphema patients have poor visual outcome as a result of associated sequelae such as vitreous hemorrhage, retinal detachment, or open globe [<a href="#rid25">25,26</a>]. Sympathetic ophthalmia (autoimmune-mediated inflammation of one or both eyes typically associated with penetrating eye trauma) has been reported in one case of nonpenetrating ocular injury with hyphema [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preexisting conditions</strong> – Patients with preexisting sickle hemoglobinopathy or bleeding dyscrasia are at higher risk of permanent vision loss [<a href="#rid2">2-4</a>].</p><p></p><p class="headingAnchor" id="H21824524"><span class="h1">TRAUMATIC GLAUCOMA</span><span class="headingEndMark"> — </span>Ghost cell glaucoma occurs when old red blood cells, distorted after losing their hemoglobin travel into the anterior chamber from the vitreous cavity and clog the trabecular meshwork [<a href="#rid28">28</a>]. Patients can develop late ghost cell glaucoma up to three months following hyphemas or vitreous hemorrhage. For this reason, intraocular pressure (IOP) should be checked one week after the hyphema has resolved and, if IOP is controlled, once more at four to eight weeks after the injury.</p><p>Blunt eye injury and hyphema can also place the patient at a long-term risk of developing other forms of traumatic glaucoma. Angle recession is present in up to 85 percent of patients with hyphema, thereby further elevating the risk [<a href="#rid11">11,29</a>]. Open or closed angle glaucoma may result. For this reason, all patients who have had a traumatic hyphema warrant regular measurement of intraocular pressure annually.</p><p>Traumatic glaucoma can be managed initially by eyedrops; however, it may progress to the point of requiring surgical intervention. (See  <a class="medical medical_review" href="/d/html/15695.html" rel="external">"Open-angle glaucoma: Treatment"</a> and  <a class="medical medical_review" href="/d/html/6903.html" rel="external">"Angle-closure glaucoma", section on 'Secondary angle-closure glaucoma'</a>.)</p><p class="headingAnchor" id="H714240982"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of approach</strong> – The clinician should first address life-threatening and immediate vision-threatening conditions (ie, orbital compartment syndrome or open globe) before proceeding with specific treatment of a traumatic hyphema. A rapid overview summarizes the important clinical features and initial management of traumatic hyphema  (<a class="graphic graphic_table graphicRef74146" href="/d/graphic/74146.html" rel="external">table 1</a>). (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for emergency ophthalmology consultation</strong> – Patients with the following conditions warrant emergency consultation with an ophthalmologist (see <a class="local">'Indications for ophthalmology consultation or referral'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orbital compartment syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>An open globe</p><p class="bulletIndent2"><span class="glyph">•</span>Large hyphemas (grade III or IV  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef71507" href="/d/graphic/71507.html" rel="external">picture 3</a>))</p><p class="bulletIndent2"><span class="glyph">•</span>Hyphemas associated with intraocular hypertension</p><p class="bulletIndent2"><span class="glyph">•</span>Hyphemas occurring in patients with bleeding tendency, sickle cell trait, or sickle hemoglobinopathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ophthalmology referral and management</strong> – An ophthalmologist should direct ongoing care of patients with traumatic hyphema to prevent rebleeding and intraocular hypertension. If prompt consultation with an ophthalmologist is not feasible but serious associated eye injury and elevated intraocular pressure can be reliably excluded, discussion with an ophthalmologist prior to emergency department discharge is suggested. These patients warrant timely referral for complete ophthalmologic examination within 24 hours. Daily comprehensive eye examinations, including measurement of intraocular pressure, are a key component of definitive care. (See <a class="local">'Ophthalmologic management'</a> above and <a class="local">'Monitoring of intraocular pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye shield and activity restriction</strong> – Patients should wear an eye shield and restrict activity for at least one week or until the hyphema resolves if still present at one week after injury. (See <a class="local">'Limitation of activity'</a> above and <a class="local">'Eye shield'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cycloplegia</strong> – For the management of pain, we suggest that patients without narrow angle glaucoma be treated with cycloplegic eye drops (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Cycloplegia may also prevent the formation of posterior synechiae. Oral or intravenous analgesics, other than nonsteroidal antiinflammatory agents, may also be given if cycloplegia is contraindicated or does not provide adequate pain control. (See <a class="local">'Cycloplegia'</a> above and <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids </strong>– We suggest that patients with traumatic hyphema receive topical glucocorticoid eye drops rather than systemic glucocorticoids to prevent rebleeding and to control inflammation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients receiving topical glucocorticoid drops require frequent serial examinations by an ophthalmologist to ensure no infection or corneal perforation occurs. (See <a class="local">'Glucocorticoid eye drops'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient with intraocular hypertension</strong> – Patients with traumatic hyphema and intraocular hypertension (intraocular pressure greater than 22 mmHg) require medication to decrease intraocular pressure (eg, topical beta adrenergic blocker eye drops or, except in patients with sickle cell hemoglobinopathy, carbonic anhydrase inhibiting eye drops)  (<a class="graphic graphic_table graphicRef76771" href="/d/graphic/76771.html" rel="external">table 3</a>). (See <a class="local">'Patients with intraocular hypertension'</a> above.)</p><p></p><p class="bulletIndent1">Transcorneal oxygen is an option for patients with hyphemas and sickle hemoglobinopathy who do not respond to topical therapy for intraocular hypertension and are not eligible for treatment with carbonic anhydrase inhibitors or <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>. (See <a class="local">'Patients with intraocular hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient with rebleeding hyphema </strong>– Patients who have rebled should be admitted to the hospital for close observation, frequent monitoring of intraocular pressure, and enforcement of limited activity. The use of antifibrinolytic agents (eg, <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a>, <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a>) has largely fallen out of favor. These agents reduce the risk of rebleeding, but limited evidence shows no benefit in terms of final visual acuity. (See <a class="local">'Patients with rebleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for surgery</strong> – Potential indications for surgical anterior chamber clot evacuation include (see <a class="local">'Surgical clot evacuation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large persistent hyphemas (≥grade III for &gt;10 days)  (<a class="graphic graphic_figure graphicRef60334" href="/d/graphic/60334.html" rel="external">figure 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Early corneal blood staining</p><p class="bulletIndent2"><span class="glyph">•</span>Uncontrolled intraocular pressure (ie, ≥50 mmHg for &gt;5 days or, in patients with sickle hemoglobinopathy, &gt;25 mmHg for &gt;24 hours) despite maximal medical therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition</strong> – Hospital admission is warranted for patients with bleeding dyscrasia, sickle cell trait, or sickle hemoglobinopathy; patients with uncontrolled intraocular hypertension on initial examination; grade III or IV hyphemas; or a hyphema that has rebled. Otherwise, patients with traumatic hyphemas who can adhere to the rigorous treatment regimen can be managed as outpatients. (See <a class="local">'Disposition'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mowafi HA, Aldossary N, Ismail SA, Alqahtani J. Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation. Br J Anaesth 2008; 100:485.</a></li><li><a class="nounderline abstract_t">Sankar PS, Chen TC, Grosskreutz CL, Pasquale LR. Traumatic hyphema. Int Ophthalmol Clin 2002; 42:57.</a></li><li><a class="nounderline abstract_t">Brandt MT, Haug RH. Traumatic hyphema: a comprehensive review. J Oral Maxillofac Surg 2001; 59:1462.</a></li><li><a class="nounderline abstract_t">Walton W, Von Hagen S, Grigorian R, Zarbin M. Management of traumatic hyphema. Surv Ophthalmol 2002; 47:297.</a></li><li><a class="nounderline abstract_t">Pollock T, Laliberté I, Wu J, Lyons C. Traumatic hyphema and immune thrombocytopenic purpura: late rebleeds associated with low platelet count. Can J Ophthalmol 2008; 43:717.</a></li><li><a class="nounderline abstract_t">Wilker SC, Singh A, Ellis FJ. Recurrent bleeding following traumatic hyphema due to mild hemophilia B (Christmas disease). J AAPOS 2007; 11:622.</a></li><li><a class="nounderline abstract_t">Woreta FA, Lindsley KB, Gharaibeh A, et al. Medical interventions for traumatic hyphema. Cochrane Database Syst Rev 2023; 3:CD005431.</a></li><li><a class="nounderline abstract_t">Wright KW, Sunalp M, Urrea P. Bed rest versus activity ad lib in the treatment of small hyphemas. Ann Ophthalmol 1988; 20:143.</a></li><li><a class="nounderline abstract_t">Fong LP. Secondary hemorrhage in traumatic hyphema. Predictive factors for selective prophylaxis. Ophthalmology 1994; 101:1583.</a></li><li><a class="nounderline abstract_t">Ng CS, Strong NP, Sparrow JM, Rosenthal AR. Factors related to the incidence of secondary haemorrhage in 462 patients with traumatic hyphema. Eye (Lond) 1992; 6 ( Pt 3):308.</a></li><li><a class="nounderline abstract_t">Agapitos PJ, Noel LP, Clarke WN. Traumatic hyphema in children. Ophthalmology 1987; 94:1238.</a></li><li><a class="nounderline abstract_t">Crouch ER Jr, Crouch ER. Management of traumatic hyphema: therapeutic options. J Pediatr Ophthalmol Strabismus 1999; 36:238.</a></li><li><a class="nounderline abstract_t">Romano PE, Robinson JA. Traumatic hyphema: a comprehensive review of the past half century yields 8076 cases for which specific medical treatment reduces rebleeding 62%, from 13% to 5% (P&lt;.0001). Binocul Vis Strabismus Q 2000; 15:175.</a></li><li class="breakAll">Hyphema and microhyphema. In: The Wills Eye Manual:  Office and Emergency Room Diagnosis and Treatment of Eye Disease, 5th edition, Ehlers JP, Shah CP (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.19.</li><li><a class="nounderline abstract_t">Karkhaneh R, Naeeni M, Chams H, et al. Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema. Eur J Ophthalmol 2003; 13:57.</a></li><li><a class="nounderline abstract_t">Pieramici DJ, Goldberg MF, Melia M, et al. A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema. Ophthalmology 2003; 110:2106.</a></li><li><a class="nounderline abstract_t">Crouch ER Jr, Williams PB, Gray MK, et al. Topical aminocaproic acid in the treatment of traumatic hyphema. Arch Ophthalmol 1997; 115:1106.</a></li><li><a class="nounderline abstract_t">Benner JD. Transcorneal oxygen therapy for glaucoma associated with sickle cell hyphema. Am J Ophthalmol 2000; 130:514.</a></li><li><a class="nounderline abstract_t">Mir T, Iftikhar M, Seidel N, et al. Clinical Characteristics and Outcomes of Hyphema in Patients with Sickle Cell Trait: 10-Year Experience at the Wilmer Eye Institute. Clin Ophthalmol 2020; 14:4165.</a></li><li><a class="nounderline abstract_t">Shiuey Y, Lucarelli MJ. Traumatic hyphema: outcomes of outpatient management. Ophthalmology 1998; 105:851.</a></li><li><a class="nounderline abstract_t">Witteman GJ, Brubaker SJ, Johnson M, Marks RG. The incidence of rebleeding in traumatic hyphema. Ann Ophthalmol 1985; 17:525.</a></li><li><a class="nounderline abstract_t">Galvis V, Pedraza-Concha A, Tello A, et al. Clinical features, management and visual outcomes on patients with traumatic hyphema in a reference ophthalmological clinic in Colombia. Rom J Ophthalmol 2020; 64:28.</a></li><li><a class="nounderline abstract_t">Edwards WC, Layden WE. Traumatic hyphema. A report of 184 consecutive cases. Am J Ophthalmol 1973; 75:110.</a></li><li><a class="nounderline abstract_t">Berríos RR, Dreyer EB. Traumatic hyphema. Int Ophthalmol Clin 1995; 35:93.</a></li><li><a class="nounderline abstract_t">Read JE, Goldberg MF. Blunt ocular trauma and hyphema. Int Ophthalmol Clin 1974; 14:57.</a></li><li><a class="nounderline abstract_t">Read J. Traumatic hyphema: surgical vs medical management. Ann Ophthalmol 1975; 7:659.</a></li><li><a class="nounderline abstract_t">Bakri SJ, Peters GB 3rd. Sympathetic ophthalmia after a hyphema due to nonpenetrating trauma. Ocul Immunol Inflamm 2005; 13:85.</a></li><li><a class="nounderline abstract_t">Campbell DG. Ghost cell glaucoma following trauma. Ophthalmology 1981; 88:1151.</a></li><li><a class="nounderline abstract_t">Kennedy RH, Brubaker RF. Traumatic hyphema in a defined population. Am J Ophthalmol 1988; 106:123.</a></li></ol></div><div id="topicVersionRevision">Topic 95661 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285392" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131583" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732035" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Traumatic hyphema: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12161209" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020640" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Traumatic hyphema and immune thrombocytopenic purpura: late rebleeds associated with low platelet count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720569" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrent bleeding following traumatic hyphema due to mild hemophilia B (Christmas disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36912744" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Medical interventions for traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3377385" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bed rest versus activity ad lib in the treatment of small hyphemas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090460" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Secondary hemorrhage in traumatic hyphema. Predictive factors for selective prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1446767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Factors related to the incidence of secondary haemorrhage in 462 patients with traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3684201" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Traumatic hyphema in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10505828" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of traumatic hyphema: therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893461" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Traumatic hyphema: a comprehensive review of the past half century yields 8076 cases for which specific medical treatment reduces rebleeding 62%, from 13% to 5% (P&lt;.0001).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893461" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Traumatic hyphema: a comprehensive review of the past half century yields 8076 cases for which specific medical treatment reduces rebleeding 62%, from 13% to 5% (P&lt;.0001).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12635675" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597516" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A phase III, multicenter, randomized, placebo-controlled clinical trial of topical aminocaproic acid (Caprogel) in the management of traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9298049" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Topical aminocaproic acid in the treatment of traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11024424" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transcorneal oxygen therapy for glaucoma associated with sickle cell hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33293789" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical Characteristics and Outcomes of Hyphema in Patients with Sickle Cell Trait: 10-Year Experience at the Wilmer Eye Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593386" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Traumatic hyphema: outcomes of outpatient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4062157" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The incidence of rebleeding in traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32292855" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical features, management and visual outcomes on patients with traumatic hyphema in a reference ophthalmological clinic in Colombia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4684253" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Traumatic hyphema. A report of 184 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751138" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Traumatic hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4465331" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Blunt ocular trauma and hyphema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1137285" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Traumatic hyphema: surgical vs medical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804775" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sympathetic ophthalmia after a hyphema due to nonpenetrating trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7335322" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ghost cell glaucoma following trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400754" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Traumatic hyphema in a defined population.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
